B
BioMarin Pharmaceutical
Biotech & Life Sciences · San Rafael, United States · Founded 1997 · IPO 1999 Unicorn
Investors
3 investors on BioMarin Pharmaceutical's cap table
Sourced from Dealroom's funding history. Investor profile links are shown where available.
BioMarin Pharmaceutical mafia
Startups founded by BioMarin Pharmaceutical alumni
Former BioMarin Pharmaceutical employees who went on to start their own companies. Sorted by Dealroom signal score.
James SabryUnited States
Agnes RafalkoUnited States
Emil D. KakkisUnited States
Matthew PattersonUnited States
Genine WInslowUnited States
Kyle SchusterUnited StatesGlobal footprint
Where BioMarin Pharmaceutical has talent and traffic
Patent intelligence
$317M patent portfolio · 124 active families
Where BioMarin Pharmaceutical concentrates vs peers
Each axis is a top-10 topic across BioMarin Pharmaceutical and its closest peers. #1 = 100, #10 = 10, absent = 0.
Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.
Capital deployed
BioMarin Pharmaceutical's 6 investments and acquisitions.
Every disclosed deal where BioMarin Pharmaceutical appeared as a backer or acquirer, 2010–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
6 deals across BioMarin Pharmaceutical's capital deployment.
Where the deals concentrate by sector, stage, and decade.
01 · Deployment strategy vs peers
Where BioMarin Pharmaceutical deploys vs peers
Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.
02 · Portfolio market map
BioMarin Pharmaceutical's portfolio, mapped.
Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.
Market sentiment
What the market is saying about BioMarin Pharmaceutical
An AI-synthesized read of the highest-engagement posts about BioMarin Pharmaceutical on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BioMarin Pharmaceutical on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.